Lupin launches generic version of kidney disorder treatment drug in US

Lupin Ltd has launched generic Tolvaptan tablets in the US, after receiving USFDA approval. These tablets, with strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, are bioequivalent to Jynarque and indicated for slowing kidney function decline in adults with ADPKD. Lupin holds exclusive first-to-file status, granting them 180-day generic drug exclusivity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mp5Ryax
via IFTTT

0 comments:

Post a Comment